Loading viewer...
investor_presentation
Format: PDF investor_presentation
2CRSi reported H1 2020/21 revenue of €78.5m with EBITDA of €1.1m, impacted by COVID-related procurement costs and staff investments. The company achieved steady progress on strategic priorities including Boston Limited integration and confirmed full-year guidance with solid H2 sales momentum.
investor_presentation
32 Pages
Lithium Americas Corp.
Virpax Pharmaceuticals VRPX 2024 Investor Presentation
investor_presentationinvestor_presentation
29 Pages
Virpax Pharmaceuticals, Inc.